In ChemBioChem we describe the employment of Nextera’s pVII peptide phage display technology in the fine-mapping of FSAP enzyme substrate specificity, which shows surprising new results.
CEO Geir Åge Løset and CBO Ole Henrik Brekke will attend the BIO Europe Spring Digital conference March 23rd – 25th.
The Nextera patent “Multivalent phage display systems and methods” was granted by the USPTO 8.1.2020.
January 1st. Dr. Ole Henrik Brekke joined Nextera as the Chief Business Officer. Ole Henrik has a strong track record in developing companies from the idea stage into successful clinical stage.
A better understanding of immunological principles is at the core of Nextera’s efforts to contribute to robust drug development in complex diseases.